TSHA
Taysha Gene Therapies, Inc.$4.42-0.14 (-3.07%)Prev Close$4.56·MCap$1.10B·P/E—·Vol1.81M·Yield—
▲
Buys (12M)
1
$2.06M
▼
Sells (12M)
9
$5.48M
◆
Net Activity
Net Seller
$3.42M
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Taysha Gene Therapies, Inc. (TSHA) has been dominated by selling, with 1 insider purchase totaling $2.06M and 9 insider sales totaling $5.48M. The most recent insider transaction was by Alam Kamran (CHIEF FINANCIAL OFFICER), who sold $7.5K worth of shares on Feb 4, 2026. Taysha Gene Therapies, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.10B.
TSHA Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 1,655 | $4.52 | $7.5K | 0 |
| Jan 23, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 102,817 | $4.72 | $485.0K | 0 |
| Jan 23, 2026 | Nagendran Sukumar | President and Head of R&D | Sell | 116,050 | $4.72 | $547.5K | 0 |
| Jan 23, 2026 | Nolan Sean P. | Chief Executive Officer | Sell | 178,101 | $4.72 | $840.2K | 0 |
| Jan 12, 2026 | Nagendran Sukumar | President and Head of R&D | Sell | 200,000 | $4.71 | $942.0K | 0 |
| Nov 28, 2025 | Nagendran Sukumar | President and Head of R&D | Sell | 370,172 | $4.58 | $1.70M | 0 |
| Sep 10, 2025 | Nagendran Sukumar | President and Head of R&D | Sell | 200,000 | $3.23 | $646.0K | 0 |
| Aug 21, 2025 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 54,491 | $2.85 | $155.3K | 0 |
| Aug 21, 2025 | Nagendran Sukumar | President and Head of R&D | Sell | 57,054 | $2.85 | $162.6K | 0 |
| May 30, 2025 | Manning Paul B | 10% Owner | Buy | 750,000 | $2.75 | $2.06M | 0 |
| Mar 11, 2025 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 29,843 | $1.69 | $50.4K | 0 |
| Jul 1, 2024 | Manning Paul B | Buy | 1,333,333 | $2.25 | $3.00M | 1,333,333 | |
| Nov 20, 2023 | Manning Paul B | 10% Owner | Buy | 100,000 | $1.63 | $163.0K | 16,566,667 |
| Aug 25, 2023 | Alam Kamran | Chief Financial Officer | Sell | 33,000 | $2.33 | $76.9K | 258,042 |
| Aug 16, 2023 | Donenberg Phillip B. | Director | Buy | 111,111 | $0.90 | $100.0K | 114,111 |
| Aug 16, 2023 | Manning Paul B | 10% Owner | Buy | 16,466,667 | $0.90 | $14.82M | 16,466,667 |
| Aug 16, 2023 | Nolan Sean P. | Chief Executive Officer | Buy | 444,444 | $0.90 | $400.0K | 1,535,545 |
| Aug 16, 2023 | Stalfort John A III | Director | Buy | 388,889 | $0.90 | $350.0K | 884,290 |
| Jul 14, 2023 | Session R.A. II | Sell | 85,872 | $0.71 | $60.8K | 8,877,091 | |
| Jun 26, 2023 | Session R.A. II | 10% Owner | Sell | 28,608 | $0.70 | $20.1K | 8,975,719 |
| Jun 22, 2023 | Session R.A. II | 10% Owner | Sell | 434,615 | $0.71 | $307.8K | 9,125,189 |
| May 18, 2023 | Nagendran Sukumar | President and Head of R&D | Buy | 5,000 | $0.68 | $3.4K | 34,226 |
| Nov 2, 2022 | Manning Paul B | Director | Buy | 1,500,000 | $2.00 | $3.00M | 1,642,202 |
| Aug 24, 2022 | Alam Kamran | Chief Financial Officer | Sell | 3,325 | $3.47 | $11.5K | 266,121 |
| Aug 22, 2022 | Alam Kamran | Chief Financial Officer | Sell | 28,675 | $3.70 | $106.0K | 290,645 |
| Jul 7, 2022 | PRASAD SUYASH | CMO and Head of R&D | Sell | 12,861 | $3.70 | $47.6K | 539,545 |
| Jul 1, 2022 | PRASAD SUYASH | CMO and Head of R&D | Sell | 50,139 | $3.65 | $183.1K | 581,265 |
| Feb 4, 2022 | Manning Paul B | Director | Buy | 201,602 | $7.80 | $1.57M | 2,091,704 |
| Feb 3, 2022 | Donenberg Phillip B. | Director | Buy | 3,000 | $7.78 | $23.3K | 3,000 |
| Feb 3, 2022 | Nagendran Sukumar | Director | Buy | 10,000 | $8.01 | $80.1K | 29,226 |
| Dec 8, 2021 | Session R.A. II | President and CEO | Buy | 42,518 | $12.44 | $529.1K | 9,190,920 |
| Nov 29, 2021 | Manning Paul B | Director | Buy | 2,202 | $13.19 | $29.0K | 34,202 |
| Nov 24, 2021 | Manning Paul B | Director | Buy | 20,000 | $12.54 | $250.8K | 32,000 |
| Aug 20, 2021 | Alam Kamran | Chief Financial Officer | Sell | 33,000 | $16.88 | $557.0K | 319,928 |
| Jul 1, 2021 | PRASAD SUYASH | CMO and Head of R&D | Sell | 79,000 | $22.63 | $1.79M | 637,533 |
| May 24, 2021 | Nolan Sean P. | Director | Buy | 1,170 | $22.35 | $26.1K | 1,170 |
| May 17, 2021 | Manning Paul B | Director | Buy | 12,000 | $20.98 | $251.8K | 12,000 |
TSHA Insider Buying Activity
The following table shows recent insider purchases of Taysha Gene Therapies, Inc. (TSHA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 30, 2025 | Manning Paul B | 10% Owner | Buy | 750,000 | $2.75 | $2.06M | 0 |
| Jul 1, 2024 | Manning Paul B | Buy | 1,333,333 | $2.25 | $3.00M | 1,333,333 | |
| Nov 20, 2023 | Manning Paul B | 10% Owner | Buy | 100,000 | $1.63 | $163.0K | 16,566,667 |
| Aug 16, 2023 | Donenberg Phillip B. | Director | Buy | 111,111 | $0.90 | $100.0K | 114,111 |
| Aug 16, 2023 | Manning Paul B | 10% Owner | Buy | 16,466,667 | $0.90 | $14.82M | 16,466,667 |
| Aug 16, 2023 | Nolan Sean P. | Chief Executive Officer | Buy | 444,444 | $0.90 | $400.0K | 1,535,545 |
| Aug 16, 2023 | Stalfort John A III | Director | Buy | 388,889 | $0.90 | $350.0K | 884,290 |
| May 18, 2023 | Nagendran Sukumar | President and Head of R&D | Buy | 5,000 | $0.68 | $3.4K | 34,226 |
| Nov 2, 2022 | Manning Paul B | Director | Buy | 1,500,000 | $2.00 | $3.00M | 1,642,202 |
| Feb 4, 2022 | Manning Paul B | Director | Buy | 201,602 | $7.80 | $1.57M | 2,091,704 |
| Feb 3, 2022 | Donenberg Phillip B. | Director | Buy | 3,000 | $7.78 | $23.3K | 3,000 |
| Feb 3, 2022 | Nagendran Sukumar | Director | Buy | 10,000 | $8.01 | $80.1K | 29,226 |
| Dec 8, 2021 | Session R.A. II | President and CEO | Buy | 42,518 | $12.44 | $529.1K | 9,190,920 |
| Nov 29, 2021 | Manning Paul B | Director | Buy | 2,202 | $13.19 | $29.0K | 34,202 |
| Nov 24, 2021 | Manning Paul B | Director | Buy | 20,000 | $12.54 | $250.8K | 32,000 |
| May 24, 2021 | Nolan Sean P. | Director | Buy | 1,170 | $22.35 | $26.1K | 1,170 |
| May 17, 2021 | Manning Paul B | Director | Buy | 12,000 | $20.98 | $251.8K | 12,000 |
TSHA Insider Selling Activity
The following table shows recent insider sales of Taysha Gene Therapies, Inc. (TSHA) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 1,655 | $4.52 | $7.5K | 0 |
| Jan 23, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 102,817 | $4.72 | $485.0K | 0 |
| Jan 23, 2026 | Nagendran Sukumar | President and Head of R&D | Sell | 116,050 | $4.72 | $547.5K | 0 |
| Jan 23, 2026 | Nolan Sean P. | Chief Executive Officer | Sell | 178,101 | $4.72 | $840.2K | 0 |
| Jan 12, 2026 | Nagendran Sukumar | President and Head of R&D | Sell | 200,000 | $4.71 | $942.0K | 0 |
| Nov 28, 2025 | Nagendran Sukumar | President and Head of R&D | Sell | 370,172 | $4.58 | $1.70M | 0 |
| Sep 10, 2025 | Nagendran Sukumar | President and Head of R&D | Sell | 200,000 | $3.23 | $646.0K | 0 |
| Aug 21, 2025 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 54,491 | $2.85 | $155.3K | 0 |
| Aug 21, 2025 | Nagendran Sukumar | President and Head of R&D | Sell | 57,054 | $2.85 | $162.6K | 0 |
| Mar 11, 2025 | Alam Kamran | CHIEF FINANCIAL OFFICER | Sell | 29,843 | $1.69 | $50.4K | 0 |
| Aug 25, 2023 | Alam Kamran | Chief Financial Officer | Sell | 33,000 | $2.33 | $76.9K | 258,042 |
| Jul 14, 2023 | Session R.A. II | Sell | 85,872 | $0.71 | $60.8K | 8,877,091 | |
| Jun 26, 2023 | Session R.A. II | 10% Owner | Sell | 28,608 | $0.70 | $20.1K | 8,975,719 |
| Jun 22, 2023 | Session R.A. II | 10% Owner | Sell | 434,615 | $0.71 | $307.8K | 9,125,189 |
| Aug 24, 2022 | Alam Kamran | Chief Financial Officer | Sell | 3,325 | $3.47 | $11.5K | 266,121 |
| Aug 22, 2022 | Alam Kamran | Chief Financial Officer | Sell | 28,675 | $3.70 | $106.0K | 290,645 |
| Jul 7, 2022 | PRASAD SUYASH | CMO and Head of R&D | Sell | 12,861 | $3.70 | $47.6K | 539,545 |
| Jul 1, 2022 | PRASAD SUYASH | CMO and Head of R&D | Sell | 50,139 | $3.65 | $183.1K | 581,265 |
| Aug 20, 2021 | Alam Kamran | Chief Financial Officer | Sell | 33,000 | $16.88 | $557.0K | 319,928 |
| Jul 1, 2021 | PRASAD SUYASH | CMO and Head of R&D | Sell | 79,000 | $22.63 | $1.79M | 637,533 |
TSHA Insiders
Similar Stocks to TSHA
VRTX
Vertex Pharmaceuticals Incorporated
$454.59-0.78%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$734.13-0.47%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$314.58+1.12%
$42.07B
INSM
Insmed Incorporated
$138.46-3.85%
$30.07B
UTHR
United Therapeutics Corporation
$523.87-0.62%
$23.50B
MRNA
Moderna, Inc.
$51.29-2.04%
$20.76B
ROIV
Roivant Sciences Ltd.
$27.16-2.37%
$20.08B
RPRX
Royalty Pharma plc
$45.36-0.37%
$19.56B